Daiichi Sankyo plans to invest approximately $1.9 billion to build manufacturing facilities for cancer drugs in Japan, the U.S., Germany, and China, according to Nikkei. The facilities are part of a strategy to diversify its production capabilities for cancer treatments, including antibody-drug conjugate (ADC) ENHERTU. As reported, the expansion aims to mitigate potential tariffs or regulatory changes between countries that could affect the company’s supply chain and distribution network. By ...